133 related articles for article (PubMed ID: 31070007)
1. Circulating complement-1q tumor necrosis factor-α-related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin.
Zhang C; Luo Y; Liu R; Li X; Yang M; Zhang Y; Li L; Mou H; Guo L; Li J; Liu H; Yang G; Zhang X
J Diabetes Investig; 2020 Jan; 11(1):88-95. PubMed ID: 31070007
[TBL] [Abstract][Full Text] [Related]
2. Correlation of serum C1q-tumour necrosis factor-related protein 5 levels with metabolic parameters and carotid intima-media thickness in newly diagnosed type 2 diabetes mellitus patients.
Uçar İMB; Çalan M; Tatar E; Chousein R; Fenercioğlu ÖE; Bozkaya G; Yüksel A
Hormones (Athens); 2020 Dec; 19(4):559-564. PubMed ID: 32594414
[TBL] [Abstract][Full Text] [Related]
3. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.
So A; Sakaguchi K; Okada Y; Morita Y; Yamada T; Miura H; Otowa-Suematsu N; Nakamura T; Komada H; Hirota Y; Tamori Y; Ogawa W
Endocr J; 2020 May; 67(5):501-507. PubMed ID: 32023587
[TBL] [Abstract][Full Text] [Related]
4. Myonectin Predicts the Development of Type 2 Diabetes.
Li K; Liao X; Wang K; Mi Q; Zhang T; Jia Y; Xu X; Luo X; Zhang C; Liu H; Zhen H; Li L; Yang G
J Clin Endocrinol Metab; 2018 Jan; 103(1):139-147. PubMed ID: 29161407
[TBL] [Abstract][Full Text] [Related]
5. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center.
Calapkulu M; Cander S; Gul OO; Ersoy C
Diabetes Metab Syndr; 2019; 13(2):1031-1034. PubMed ID: 31336439
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
[TBL] [Abstract][Full Text] [Related]
8. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
Shin Y; Choi H; Lim S
Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498
[TBL] [Abstract][Full Text] [Related]
9. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
Elkazzaz SK; Khodeer DM; El Fayoumi HM; Moustafa YM
Life Sci; 2021 Sep; 280():119018. PubMed ID: 33549594
[TBL] [Abstract][Full Text] [Related]
10. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
Yamakage H; Tanaka M; Inoue T; Odori S; Kusakabe T; Satoh-Asahara N
J Diabetes Investig; 2020 May; 11(3):653-661. PubMed ID: 31721467
[TBL] [Abstract][Full Text] [Related]
11. The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Sato T; Aizawa Y; Yuasa S; Kishi S; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Sato M; Okabe M
Cardiovasc Diabetol; 2018 Jan; 17(1):6. PubMed ID: 29301516
[TBL] [Abstract][Full Text] [Related]
12. Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center.
Calapkulu M; Cander S; Gul OO; Ersoy C
Diabetes Metab Syndr; 2019; 13(1):284-288. PubMed ID: 30641713
[TBL] [Abstract][Full Text] [Related]
13. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
[TBL] [Abstract][Full Text] [Related]
15. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
16. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Ott C; Jumar A; Striepe K; Friedrich S; Karg MV; Bramlage P; Schmieder RE
Cardiovasc Diabetol; 2017 Feb; 16(1):26. PubMed ID: 28231831
[TBL] [Abstract][Full Text] [Related]
17. Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort.
Jensen M; Eickhoff MK; Persson F; Rossing P; Thiel S; Hansen SWK; Palarasah Y; Svenningsen P; Jensen BL
Immunobiology; 2024 May; 229(3):152797. PubMed ID: 38518448
[TBL] [Abstract][Full Text] [Related]
18. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study.
Emamgholipour S; Moradi N; Beigy M; Shabani P; Fadaei R; Poustchi H; Doosti M
Diabetol Metab Syndr; 2015; 7():108. PubMed ID: 26613006
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Ghanim H; Abuaysheh S; Hejna J; Green K; Batra M; Makdissi A; Chaudhuri A; Dandona P
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32044999
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM
Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
